Research programme: mar operon inhibitors - Paratek

Drug Profile

Research programme: mar operon inhibitors - Paratek

Alternative Names: MAR inhibitors - Paratek; Prophylactic biowarfare agents - Paratek

Latest Information Update: 06 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Paratek Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 12 Nov 2011 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 12 Nov 2007 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
  • 12 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial Infections antimicrobial activity and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top